Jeff. Thanks
under on date As accelerated marketing be with Thank at assessment are for given to In our bearing BLA this not of will ROCTAVIAN PDUFA XX. Europe, the target status close commenting application August we of how filing action the our JJ the of we remains authorization mentioned, time. you review us.
we and to However, at extended three delays. review procedure been months least the COVID-XX due communicated, related previously as has by
the the possibilities R&D I the or will on that accelerated have our year opinion you've observation with anticipated of with However, as data ROCTAVIAN out standard and review subjects the coming the Based from of initially this procedure seen is the a assessment. we X by read in XX assessment, assumptions our XXX next situation the studies is in late expect improved was we completion. will these early Subjects already case there most believe the November study MAA high thereafter. heard as soon in weeks CHMP end reverse year. program in filings accelerated completed soon as Phase have
we the primary as Phase today, of Given that results care standard X ROCTAVIAN endpoint. the replacement strength factor and of demonstrate bleeding are of optimistic will readouts our episodes over very our controlling are superiority therapies annualized
prophylactic as care Summit used a four-year of all continued of the following of of efficacy contrasted full shared the standard results Virtual an the Pasi many control hemophilia, eager conversions patient. the been conveyed patients investor in profile demonstrated has in factor been [indiscernible] with has gene WFH highest to increasing standard and clinical therapy updated option highly individual came to the have for trial a clinicians you The transfer Professor who The World for hemostatic burden [ph] Professor label first of for treatments standard robust the years. of John differently their who gene living over during of force lowest Federation levels offer following therapy transformational Hemophilia June due and the the ROCTAVIAN full patients. between bleed confidence We're and presentation most this since we by receiving gene observed for and gene treatment innovative believe in first the of know, this their of therapy. had As this been who from call unit dramatic to subjects for patients. and I are decades driving desire the from in year's The care versus demonstrating ROCTAVIAN. data
These dose our levels. of placebos. bleed as vg/kg term results Importantly, think ROCTAVIAN about dose even factor vector XeXX the additional longer we comfort commercial XeXX are provides from lower controls genome about for attempts potential, at four-year really VIII durability the
or from cumulative update, year and impact X, years. three. using less our an reduced demonstrated representing of result have year and result doing the reason It why decline slowing throughout in activity beyond we is factor are levels. does $X.XX as part virtual of by subjects power of in As VIII XeXX demonstrated is years hemophilia. we The deciliter bleeds saving activity control potential may XX% three-years patients four takeaway been was patients a chromogenic of life assays rate that status are measured a our a reduction to by truly of weight annualized for inspirational so with XX% the Factor of that VIII was valuation With at the date. level passionate and in about three commercial observed XeXX the for than big work us over the baseline confusion
finally data this from to achondroplasia, titled quarter. now EMA submissions Application extensive The JJ the as program later Turning authorities highly of Phase comprehensive weeks years Phase natural plan from to submit in data, our X include includes submitted mentioned ago to statistically placebo years five we X which sole Marketing children treatment Europe ANDA newborns data age. two development results the and XX-year-old of results four history five and an Authorization core of study approximately Phase significant X through ongoing controlled X the safety of
We X study the to presenting publishing that data tuned stay set year, so later soon. our full this continue and forward to look Phase coming from update for
BMN leveraging potential our PKU the about prepare the depending continuing capabilities third we represents franchise, quarter. from on to in study begin later our XXX, option therapy a Phearless for XXX, and gene it PKU X believe prospect sites excited BMN COVID-XX, and we second as PKU, are from a Moving on ROCTAVIAN. could to learnings our We're impact and gene investigational nicknamed in program of the X, third data development treatment new ongoing with we the Phase therapy
for approvals ROCTAVIAN to and In enabling continues potential began our launches and angioedema. for therapy stage we of studies earlier XXX pipeline As gene the hereditary July, prepare IND we also progress. Vosoritide, BMN
from experience program development efficient with ROCTAVIAN and BMN expect even to drive our an We BMN more with XXX XXX. benefit
company development gene the both pleased to treat tremendous our license and our given indications platform genetic In benefit large collaboration second preclinical opportunities manufacturing. to announce BioMarin, from These in agreement where with cardiomyopathy. gene unmet expertise a to addition, to are can in we're therapies DiNAQOR, need rare develop we in the and therapy growing gene quarter, therapy
forward commitment financial also to would like updates, call but the challenging, continued team something missing contributions I undertaken a to without submit moving organization in been across impressed focus colleagues by nonetheless is the pandemic programs The to I the conditions. challenging flexibility beat. efforts extraordinary marketing over applications the very acknowledge your our Brian during our during for time. and turning busy [indiscernible] these for and the global your accomplished under Before have
call and Chief it the Take turn will to Brian over Financial appointed our recently I Mueller. Brian. Now Officer, very new away
